Nov 05, 2026
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Sep 29, 2026
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
Sep 28, 2026
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Sep 08, 2026
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
Aug 03, 2026
Keros Therapeutics Reports Second Quarter 2026 Financial Results
Jul 30, 2026
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
Jun 25, 2026
Keros Therapeutics Appoints Anne Prener to its Board of Directors
Jun 01, 2026
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
May 14, 2026
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
Mar 09, 2026
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
Displaying 1 - 10 of 14